1 |
王赛凤,史蔚,谢咸晶. RNA结合基序5基因敲除子宫内膜癌细胞系及其作用研究[J]. 实用医学杂志, 2022,38(10):1203-1207. doi:10.3969/j.issn.1006-5725.2022.10.006
doi: 10.3969/j.issn.1006-5725.2022.10.006
|
2 |
ARCIUOLO D, TRAVAGLINO A, RAFFONE A, et al. TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives[J]. Int J Mol Sci, 2022,23(19):11-16. doi:10.3390/ijms231911684
doi: 10.3390/ijms231911684
|
3 |
YEN T T, WANG T L, FADER A N, et al. Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer[J]. Int J Gynecol Pathol, 2020,39(1):26-35. doi:10.1097/pgp.0000000000000585
doi: 10.1097/pgp.0000000000000585
|
4 |
ZHAO S, LI W, YU W, et al. Exosomal miR-21 from tubular cells contributes to renal fibrosis by activating fibroblasts via targeting PTEN in obstructed kidneys[J]. Theranostics, 2021,11(18):8660-8673. doi:10.7150/thno.62820
doi: 10.7150/thno.62820
|
5 |
TURNHAM D J, BULLOCK N, DASS M S, et al. The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer[J]. Cells, 2020,9(11):23-26. doi:10.3390/cells9112342
doi: 10.3390/cells9112342
|
6 |
YANG H, ZHANG H, LUAN Y, et al. Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation[J]. Nat Genet, 2022,54(2):170-179. doi:10.1038/s41588-021-00993-x
doi: 10.1038/s41588-021-00993-x
|
7 |
YEN T T, WANG T L, FADER A N, et al. Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer[J]. Int J Gynecol Pathol, 2020,39(1):26-35. doi:10.1097/pgp.0000000000000585
doi: 10.1097/pgp.0000000000000585
|
8 |
VAN DEN HEERIK A S V M, HOREWEG N, DE BOER S M, et al. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy[J]. Int J Gynecol Cancer, 2021,31(4):594-604. doi:10.1136/ijgc-2020-001822
doi: 10.1136/ijgc-2020-001822
|
9 |
REN X, LIANG J, ZHANG Y, et al. Single-cell transcriptomic analysis highlights origin and pathological process of human endometrioid endometrial carcinoma[J]. Nat Commun, 2022,13(1):6300-6308. doi:10.1038/s41467-022-33982-7
doi: 10.1038/s41467-022-33982-7
|
10 |
PASSARELLO K, KURIAN S, VILLANUEVA V. ENDOMETRIAL CANCER: An Overview of Pathophysiology, Management, and Care[J]. Semin Oncol Nurs, 2019,35(2):157-165. doi:10.1016/j.soncn.2019.02.002
doi: 10.1016/j.soncn.2019.02.002
|
11 |
REN G, LAI B, HARLY C, et al. Transcription factors TCF-1 and GATA3 are key factors for the epigenetic priming of early innate lymphoid progenitors toward distinct cell fates[J]. Immunity, 2022,55(8):1402-1413. doi:10.1016/j.immuni.2022.06.019
doi: 10.1016/j.immuni.2022.06.019
|
12 |
ZHU Z, SHEN H, XU J, et al. GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells[J]. Drug Resist Updat, 2023,69(5):10-14. doi:10.1016/j.drup.2023.100974
doi: 10.1016/j.drup.2023.100974
|
13 |
ZHANG M, WANG N, SONG P, et al. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1[J]. Cell Prolif, 2020,53(9):12-15. doi:10.1111/cpr.12855
doi: 10.1111/cpr.12855
|
14 |
EL-ARABEY A A, ABDALLA M. GATA3 as an immunomodulator in obesity-related metabolic dysfunction associated with fatty liver disease, insulin resistance, and type 2 diabetes[J]. Chem Biol Interact, 2022,366(7):11-14. doi:10.1016/j.cbi.2022.110141
doi: 10.1016/j.cbi.2022.110141
|
15 |
QU Y Y, ZHAO R, ZHANG H L, et al. Inactivation of the AMPK-GATA3-ECHS1 Pathway Induces Fatty Acid Synthesis That Promotes Clear Cell Renal Cell Carcinoma Growth[J]. Cancer Res, 2020,80(2):319-333. doi:10.1158/0008-5472.can-19-1023
doi: 10.1158/0008-5472.can-19-1023
|
16 |
FERRER A I, EINSTEIN E, MORELLI S S. Bone Marrow-Derived Cells in Endometrial Cancer Pathogenesis: Insights from Breast Cancer[J]. Cells, 2022,11(4):714. doi:10.3390/cells11040714
doi: 10.3390/cells11040714
|
17 |
GE X, LI M, YIN J, et al. Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma[J]. Mol Cell, 2022,82(7):1249-1260. doi:10.1016/j.molcel.2022.01.029
doi: 10.1016/j.molcel.2022.01.029
|
18 |
KMIOLEK T, PARADOWSKA-GORYCKA A. miRNAs as Biomarkers and Possible Therapeutic Strategies in Rheumatoid Arthritis[J]. Cells, 2022,11(3):452. doi:10.3390/cells11030452
doi: 10.3390/cells11030452
|
19 |
袁峰,张书力,李少军,等. 血清miR-21、缺氧诱导因子-1α水平在带状疱疹患者治疗前后变化及评估后遗神经痛的分析[J]. 实用医学杂志, 2023,39(3):364-368. doi:10.3969/j.issn.1006-5725.2023.03.018
doi: 10.3969/j.issn.1006-5725.2023.03.018
|
20 |
HASHEMI M, MIRDAMADI M S A, TALEBI Y, et al. Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents[J]. Pharmacol Res, 2023,187(7):10-18. doi:10.1016/j.phrs.2022.106568
doi: 10.1016/j.phrs.2022.106568
|
21 |
BIBO-VERDUGO B, SALVESEN G S. Caspase mechanisms in the regulation of inflammation[J] Mol Aspects Med, 2022,88(7):10-15. doi:10.1016/j.mam.2022.101085
doi: 10.1016/j.mam.2022.101085
|
22 |
CAO K, RILEY J S, HEILIG R, et al. Mitochondrial dynamics regulate genome stability via control of caspase-dependent DNA damage[J]. Dev Cell, 2022,57(10):1211-1225. doi:10.1016/j.devcel.2022.03.019
doi: 10.1016/j.devcel.2022.03.019
|
23 |
KIELBIK M, SZULC-KIELBIK I, KLINK M. E-Cadherin Expression in Relation to Clinicopathological Parameters and Survival of Patients with Epithelial Ovarian Cancer[J]. Int J Mol Sci, 2022,23(22):14383. doi:10.3390/ijms232214383
doi: 10.3390/ijms232214383
|
24 |
YAN G, WAN Z, ZHONG Y, et al. LncRNA MCM3AP-AS1 Regulates miR-21/PTEN Axis to Affect Cervical Squamous Cell Carcinoma Cell Proliferation and Apoptosis[J]. Crit Rev Eukaryot Gene Expr, 2022,32(4):49-56. doi:10.1615/critreveukaryotgeneexpr.2022041014
doi: 10.1615/critreveukaryotgeneexpr.2022041014
|
25 |
TAN C, DU H, WANG Y, et al. LncRNA GABPB1-IT1 inhibits the tumorigenesis of renal cancer via the miR-21/PTEN axis. J Biochem Mol Toxicol, 2023,37(4):23-28. doi:10.1002/jbt.23288
doi: 10.1002/jbt.23288
|